Add to a list

Suspension of trading

Rayont Inc. Stock

RAYT

US75508M1009

Biotechnology & Medical Research

OTC Markets Traded

Market Closed - OTC Markets Other stock markets 15:16:38 2024-11-15 EST			5-day change	1st Jan Change
0.000001 ^USD	-100.00%		-.--%	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
RAYT Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	4.47M 3.91M 3.61M 3.31M 6.27M 431M 6.38M 43.08M 16.92M 210M 16.78M 16.41M 726M	P/E 2021	293x	P/E 2022	186x
Enterprise Value	12.25M 10.71M 9.9M 9.09M 17.2M 1.18B 17.49M 118M 46.39M 576M 46M 44.99M 1.99B	EV / Sales 2021	47.8x	EV / Sales 2022	18.8x
Free-Float	48.18%	Yield 2021 *	-	Yield 2022	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI
23-02-14	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
23-01-17	Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
22-12-29	Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	CI
22-12-28	Rayont Inc. Auditor Raises 'Going Concern' Doubt	CI
22-05-20	Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	CI
22-05-17	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	CI
22-04-25	Rayont Inc. Announces Management Changes	CI
22-04-22	Rayont Inc. Announces Board Resignations	CI
22-03-01	Rayont Inc. Announces Management Changes	CI
22-03-01	Rayont Inc. Announces Executive Changes	CI
22-02-24	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	CI

23-06-23	Rayont : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
23-06-23	RAYONT INC. : Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K)	AQ
23-05-05	RAYONT INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23-03-31	RAYONT INC. : Financial Statements and Exhibits (form 8-K)	AQ
23-02-24	RAYONT INC. : Change in Directors or Principal Officers (form 8-K)	AQ

3 years	0		0.25
5 years	0		3
10 years	0		10.4

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAYONT INC.	-100.00%	-.--%	-	-	45
LONZA GROUP AG	-0.59%	-2.56%	+0.18%	+5.51%	49.7B
REVOLUTION MEDICINES, INC.	-2.85%	-6.25%	+366.61%	+572.09%	38.09B
BEONE MEDICINES AG	+1.98%	+4.82%	+13.71%	+61.68%	35.29B
IQVIA HOLDINGS INC.	+1.78%	+0.73%	+32.68%	-4.80%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	-3.27%	-5.67%	-	-	16.14B
MEDPACE HOLDINGS, INC.	+1.64%	+0.45%	+70.86%	+121.18%	15.36B
EUROFINS SCIENTIFIC SE	+1.15%	+2.03%	+16.03%	+19.78%	13.89B
ICON PUBLIC LIMITED COMPANY	-1.21%	+0.73%	+18.02%	-30.96%	13.02B
Average	-10.59%	-0.51%	+65.31%	+96.49%	24.38B
Weighted average by Cap.	-0.80%	-0.64%	+75.85%	+116.61%

Rayont Inc. Stock

Stocks

RAYT

US75508M1009

Biotechnology & Medical Research

Valuation: Rayont Inc.

Latest news : Rayont Inc.

Press Releases: Rayont Inc.

Quotes and Performance

Course Extremes

Other Biotechnology & Medical Research

Financials

Company Profile

	2021	2022
Net sales	2.97M 2.6M 2.4M 2.2M 4.17M 286M 4.24M 28.63M 11.25M 140M 11.15M 10.91M 482M	2.84M 2.48M 2.3M 2.11M 3.99M 274M 4.06M 27.37M 10.75M 134M 10.66M 10.43M 461M
Net income	384K 336K 310K 285K 539K 36.99M 548K 3.7M 1.45M 18.06M 1.44M 1.41M 62.36M	245K 214K 198K 182K 344K 23.59M 350K 2.36M 927K 11.52M 920K 899K 39.78M
Net Debt	2.4M 2.1M 1.94M 1.78M 3.38M 232M 3.43M 23.18M 9.11M 113M 9.03M 8.83M 391M	7.78M 6.8M 6.29M 5.77M 10.92M 750M 11.11M 75M 29.46M 366M 29.22M 28.57M 1.26B